***Background.*** Our goal was to describe early implementation of Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI) identification coupled with antimicrobial stewardship program (ASP) on timing, process and outcome in bacteremic patients.

***Methods.*** MALDI at Montefiore received NYS Department of Health lab approval January 2014. A pilot for MALDI identification (IDENT) of blood cultures coupled with ASP notification (MALDI-IDENT+ ASP) was compared to a matched month of conventional IDENT (CON-IDENT) (March 2014 vs 2013) to assess feasibility and resources needed. MALDI lists were e-faxed 2-3 times/day to ASP staff who reviewed medical records for demographics, antibiotic prescribing, and timing parameters. Data collection is ongoing for statistical and program evaluation (i.e., outcomes, severity adjustment) and for pediatrics.

***Results.*** Blood cultures from 115 patients are summarized in the table. In March 2014 \>90% blood isolates were IDENT by MALDI, the majority from plates (68%) vs bottles (32%). The median time in hours to IDENT was sooner with MALDI. A trend towards earlier targeted antibiotics was also seen with MALDI-IDENT, especially for gram-negative rods (55.9 vs 85.0) and isolates identified directly from bottles (64.9 vs 77.6). These interventions required 6-10 hours daily from lab and ASP.

                                                MALDI-IDENT + ASP March.\'14 (n=62)               CON-IDENT Mar.\'13 (n=53)                         p-value
  --------------------------------------------- ------------------------------------------------- ------------------------------------------------- ---------
  **Patient Demographics**                                                                                                                          
  Age (mean years, range)                       62 (25-94)                                        68 (24-93)                                        
  Gender (% female)                             40                                                57                                                
  Clinical source (Top 3)                       Urine (13), Abdominal (10), Bone/Joint/SSTI (9)   Urine (13), Pneumonia (10), Bone/Joint/SSTI (8)   
  Sepsis (Sp) + Severe Sp/shock (%)             40                                                39                                                
  **Pathogen distribution**                                                                                                                         
  Gram negative (n=total)                       28                                                34                                                
  Gram positive (n=total, *S.aureus*, other)    47, 17, 30                                        32, 8, 24                                         
  **Timing parameters** (median hours, range)                                                                                                       
  ^A^Time to **IDENT**                          31.4 (17.1-218.2)                                 52.2 (26.5-254.3)                                 \<0.001
  ^B^Time to Antibiotic Regimen                 67.5 (19.4-185.8)                                 79.2 (33.5-241.6)                                 0.07

A= Microbiological identification--time collected; B= Preferred narrowest antibiotics--time collected

***Conclusion.*** Our preliminary results suggest shortened time to identification and tailored antibiotics. However additional data is needed for formal evaluation. Our pilot supports that MALDI can feasibly be adapted to a large urban academic center, with proper resources and close coordination between lab and ASP staff.
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